{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T07:58:17Z","timestamp":1769846297159,"version":"3.49.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Nonsteroidal anti-inflammatory drugs (NSAIDs) have been widely used in the closure of ductus arteriosus in premature infants. We aimed to develop and validate an interpretable machine-learning model for predicting the efficacy of NSAIDs for closing hemodynamically significant patent ductus arteriosus (hsPDA) in preterm infants.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We assessed 182 preterm infants \u2264 30 weeks of gestational age first treated with NSAIDs to close hsPDA. According to the treatment outcome, patients were divided into a \u201csuccess\u201d group and \u201cfailure\u201d group. Variables for analysis were demographic features, clinical features, as well as laboratory and echocardiographic parameters within 72\u2005h before medication use. We developed the machine-learning model using random forests. Model performance was assessed by the area under the receiver operating characteristic curve (AUC). Variable-importance and marginal-effect plots were constructed to explain the predictive model. The model was validated using an external cohort of two preterm infants who received ibuprofen (p.o.) to treat hsPDA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eighty-three cases (45.6%) were in the success group and 99 (54.4%) in the failure group. Infants in the success group were associated with maternal chorioamnionitis (<jats:italic>p<\/jats:italic>\u2009=\u20090.002), multiple births (<jats:italic>p<\/jats:italic>\u2009=\u20090.007), gestational age at birth (<jats:italic>p<\/jats:italic>\u2009=\u20090.020), use of indometacin (<jats:italic>p<\/jats:italic>\u2009=\u20090.007), use of inotropic agents (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001), noninvasive ventilation (<jats:italic>p<\/jats:italic>\u2009=\u20090.001), plasma albumin level (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001), PDA size (<jats:italic>p<\/jats:italic>\u2009=\u20090.038) and Vmax (<jats:italic>p<\/jats:italic>\u2009=\u20090.013). Multivariable binary logistic regression analysis showed that maternal chorioamnionitis, multiple births, use of indomethacin, use of inotropic agents, plasma albumin level, and PDA size were independent risk factors influencing the efficacy of NSAIDs (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.05). The AUC of the random forest model was 0.792. The top-three features contributing most to the model in the variable-importance plot were the plasma albumin level and platelet count 72\u2005h before treatment and 24-h urine volume before treatment. In the external cohort, treatment succeeded in one case and failed in the other. The probabilities of success and failure predicted by the random forest model were 60.2% and 48.4%, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Based on clinical, laboratory, and echocardiographic features before first-time NSAIDs treatment, we constructed an interpretable machine-learning model, which has a certain reference value for predicting the closure of hsPDA in premature infants under 30 weeks of gestational age.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2023.1097950","type":"journal-article","created":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T05:31:46Z","timestamp":1680586306000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["An interpretable machine-learning model for predicting the efficacy of nonsteroidal anti-inflammatory drugs for closing hemodynamically significant patent ductus arteriosus in preterm infants"],"prefix":"10.3389","volume":"11","author":[{"given":"Tai-Xiang","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Xin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi-Chen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Ping","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"605879","DOI":"10.3389\/fped.2020.605879","article-title":"Related factors of patent ductus arteriosus in preterm infants: a systematic review and meta-analysis","volume":"8","author":"Liu","year":"2021","journal-title":"Front Pediatr"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e20201209","DOI":"10.1542\/peds.2020-1209","article-title":"Patent ductus arteriosus of the preterm infant","volume":"146","author":"Hamrick","year":"2020","journal-title":"Pediatrics"},{"key":"B3","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.pedneo.2019.10.002","article-title":"Therapeutic strategy of patent ductus arteriosus in extremely preterm infants","volume":"61","author":"Su","year":"2020","journal-title":"Pediatr Neonatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"216","DOI":"10.2174\/1573396310666140228235815","article-title":"Clinical pharmacology of ibuprofen and indomethacin in preterm infants with patent ductus arteriosus","volume":"10","author":"Pacifici","year":"2014","journal-title":"Curr Pediatr Rev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1067\/S0022-3476(03)00303-2","article-title":"Indomethacin responsiveness of patent ductus arteriosus and renal abnormalities in preterm infants treated with indomethacin","volume":"143","author":"Itabashi","year":"2003","journal-title":"J Pediatr"},{"key":"B6","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/jp.2015.33","article-title":"Predictors of successful closure of patent ductus arteriosus with indomethacin","volume":"35","author":"Ahamed","year":"2015","journal-title":"J Perinatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1055\/s-0039-1678555","article-title":"Does postmenstrual age affect medical patent ductus arteriosus treatment success in preterm infants?","volume":"36","author":"Kaur","year":"2019","journal-title":"Am J Perinatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"729461","DOI":"10.3389\/fped.2021.729461","article-title":"Platelet count might be associated with the closure of hemodynamically significant patent ductus arteriosus","volume":"9","author":"Zhong","year":"2021","journal-title":"Front Pediatr"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jama.2018.1896","article-title":"Association of placebo, indomethacin, ibuprofen, and Acetaminophen with closure of hemodynamically significant patent ductus arteriosus in preterm infants: a systematic review and meta-analysis","volume":"319","author":"Mitra","year":"2018","journal-title":"JAMA"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1161\/CIRCULATIONAHA.115.001593","article-title":"Machine learning in medicine","volume":"132","author":"Deo","year":"2015","journal-title":"Circulation"},{"key":"B11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3233\/SHTI210854","article-title":"Medical informatics in a tension between black-box AI and trust","volume":"289","author":"Sariyar","year":"2022","journal-title":"Stud Health Technol Inform"},{"key":"B12","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.cjca.2021.09.004","article-title":"Opening the black box: the promise and limitations of explainable machine learning in cardiology","volume":"38","author":"Petch","year":"2022","journal-title":"Can J Cardiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/chd.12727","article-title":"What is a hemodynamically significant PDA in preterm infants?","volume":"14","author":"Shepherd","year":"2019","journal-title":"Congenit Heart Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/jp.2010.62","article-title":"Antenatal magnesium sulfate and the postnatal response of the ductus arteriosus to indomethacin in extremely preterm neonates","volume":"31","author":"Katayama","year":"2011","journal-title":"J Perinatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/sj.jp.7211612","article-title":"The effects of indomethacin tocolysis on the postnatal response of the ductus arteriosus to indomethacin in extremely low birth weight infants","volume":"27","author":"Cordero","year":"2007","journal-title":"J Perinatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s13312-012-0132-3","article-title":"Patent ductus arteriosus in infants <29 weeks gestation\u2013outcomes and factors affecting closure","volume":"49","author":"Popat","year":"2012","journal-title":"Indian Pediatr"},{"key":"B17","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s00246-021-02765-0","article-title":"Ductus arteriosus of extremely preterm twins is more resistant to cyclooxygenase inhibitors than those of singletons","volume":"43","author":"Ono","year":"2022","journal-title":"Pediatr Cardiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/jpc.15266","article-title":"Association between changes in urine output and successful indomethacin treatment for patent ductus arteriosus in preterm neonates","volume":"57","author":"Louis","year":"2021","journal-title":"J Paediatr Child Health"},{"key":"B19","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1055\/s-2004-829872","article-title":"Indomethacin-induced early patent ductus arteriosus closure cannot be predicted by a decrease in pulse pressure","volume":"21","author":"Lubetzky","year":"2004","journal-title":"Am J Perinatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41390-018-0077-x","article-title":"European special interest group \u2018neonatologist performed echocardiography\u2019 (NPE). application of NPE in the assessment of a patent ductus arteriosus","volume":"84","author":"van Laere","year":"2018","journal-title":"Pediatr Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1007\/s00431-022-04451-6","article-title":"Lung ultrasound score parallels trends in systemic haemodynamics after PDA ligation: a case series","volume":"181","author":"Savoia","year":"2022","journal-title":"Eur J Pediatr"},{"key":"B22","doi-asserted-by":"publisher","first-page":"6847","DOI":"10.1021\/acs.jmedchem.0c00225","article-title":"Albumin-based transport of nonsteroidal anti-inflammatory drugs in mammalian blood plasma","volume":"63","author":"Czub","year":"2020","journal-title":"J Med Chem"},{"key":"B23","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3109\/14767058.2016.1163684","article-title":"The association of platelets with failed patent ductus arteriosus closure after a primary course of indomethacin or ibuprofen: a systematic review and meta-analysis","volume":"30","author":"Mitra","year":"2017","journal-title":"J Matern Fetal Neonatal Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e20182565","DOI":"10.1542\/peds.2018-2565","article-title":"Platelet transfusion for PDA closure in preterm infants: a randomized controlled trial","volume":"143","author":"Kumar","year":"2019","journal-title":"Pediatrics"},{"key":"B25","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3109\/14767058.2011.607593","article-title":"Renal safety of non steroidal anti inflammatory drugs (NSAIDs) in the pharmacologic treatment of patent ductus arteriosus","volume":"24","author":"Fanos","year":"2011","journal-title":"J Matern Fetal Neonatal Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"CD004213","DOI":"10.1002\/14651858.CD004213.pub4","article-title":"Ibuprofen for the prevention of patent ductus arteriosus in preterm and\/or low birth weight infants","volume":"6","author":"Ohlsson","year":"2019","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1097950\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T05:31:49Z","timestamp":1680586309000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1097950\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,4]]},"references-count":26,"alternative-id":["10.3389\/fped.2023.1097950"],"URL":"https:\/\/doi.org\/10.3389\/fped.2023.1097950","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,4]]},"article-number":"1097950"}}